Galapagos will use the loans to help fund the pre-clinical development of SARM candidate drug GLPG0492 for cachexia and the antibody alliance with MorphoSys. About Galapagos’ SARM candidate drug Galapagos’ SARM candidate drug, GLPG0492, is an orally-available small molecule therapeutic, which has demonstrated successful Proof of Concept in pre-clinical studies for cachexia (the loss of weight and muscle mass). About the Galapagos-MorphoSys antibody alliance in bone and joint diseases In November 2008, Galapagos and MorphoSys entered a co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone & joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis. Galapagos provides antibody targets implicated in bone & joint disease in addition to its adenoviral target discovery platform to discover further targets for antibody development. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. read more
Technorati Tags: galapagos, antibody, alliance, development, statements, eureka, weight loss news
This entry was posted
on Thursday, November 26th, 2009 at 2:52 pm and is filed under Weight Loss News.
You can follow any responses to this entry through the RSS 2.0 feed.
Responses are currently closed, but you can trackback from your own site.
Loading ...
